Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker PLSE
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Liane Rae Teplitsky Chief Operating Officer | PLSE Pulse Biosciences, Inc | Buy | 1,001 | $49.95 | $50.0K Buy | Form 4 ↗ |
| Aug 31, 2026 | Liane Rae Teplitsky Chief Operating Officer | PLSE Pulse Biosciences, Inc | Buy | 1,024 | $48.80 | $50.0K Buy | Form 4 ↗ |
| Aug 28, 2026 | Liane Rae Teplitsky Chief Operating Officer | PLSE Pulse Biosciences, Inc | Buy | 1,034 | $48.35 | $50.0K Buy | Form 4 ↗ |
| Aug 26, 2026 | Liane Rae Teplitsky Chief Operating Officer | PLSE Pulse Biosciences, Inc | Buy | 1,036 | $48.24 | $50.0K Buy | Form 4 ↗ |
| May 11, 2026 | Robert W. Duggan Director, 10% owner | PLSE Pulse Biosciences, Inc | Buy | 660,233 | $19.69 | $13.0M Buy | Form 4/A ↗ |
| May 11, 2026 | Paul A. Laviolette Chief Executive Officer, Director | PLSE Pulse Biosciences, Inc | Buy | 15,000 | $19.69 | $295.4K Buy | Form 4/A ↗ |
| Feb 18, 2026 | Kevin Patrick Danahy Chief Commercial Officer | PLSE Pulse Biosciences, Inc | Sale | 5,000 | $23.64 | $118.2K Sale | Form 4 ↗ |
| Feb 17, 2026 | Kevin Patrick Danahy Chief Commercial Officer | PLSE Pulse Biosciences, Inc | Sale | 20,000 | $23.63 | $472.6K Sale | Form 4 ↗ |
| Feb 13, 2026 | Kevin Patrick Danahy Chief Commercial Officer | PLSE Pulse Biosciences, Inc | Sale | 20,000 | $23.53 | $470.6K Sale | Form 4 ↗ |
| Feb 12, 2026 | Kevin Patrick Danahy Chief Commercial Officer | PLSE Pulse Biosciences, Inc | Sale | 20,000 | $23.37 | $467.4K Sale | Form 4 ↗ |
| Feb 11, 2026 | Kevin Patrick Danahy Chief Commercial Officer | PLSE Pulse Biosciences, Inc | Sale | 20,000 | $25.20 | $504.0K Sale | Form 4 ↗ |
| Feb 10, 2026 | Kevin Patrick Danahy Chief Commercial Officer | PLSE Pulse Biosciences, Inc | Sale | 20,000 | $23.52 | $470.4K Sale | Form 4 ↗ |
| Feb 9, 2026 | Kevin Patrick Danahy Chief Commercial Officer | PLSE Pulse Biosciences, Inc | Sale | 20,000 | $21.45 | $429.0K Sale | Form 4 ↗ |
| Oct 2, 2025 | Kevin Patrick Danahy Chief Commercial Officer | PLSE Pulse Biosciences, Inc | Sale | 4,600 | $18.53 | $85.2K Sale | Form 4 ↗ |
| Sep 19, 2025 | Kevin Patrick Danahy Chief Commercial Officer | PLSE Pulse Biosciences, Inc | Sale | 400 | $18.48 | $7,392 Sale | Form 4 ↗ |
| Sep 18, 2025 | Kevin Patrick Danahy Chief Commercial Officer | PLSE Pulse Biosciences, Inc | Sale | 20,000 | $18.49 | $369.8K Sale | Form 4 ↗ |
| Sep 17, 2025 | Darrin Uecker Chief Technology Officer, Director | PLSE Pulse Biosciences, Inc | Sale | 20,000 | $16.21 | $324.2K Sale | Form 4 ↗ |
| Sep 16, 2025 | Darrin Uecker Chief Technology Officer, Director | PLSE Pulse Biosciences, Inc | Sale | 25,000 | $16.28 | $407.0K Sale | Form 4 ↗ |
| Sep 15, 2025 | Darrin Uecker Chief Technology Officer, Director | PLSE Pulse Biosciences, Inc | Sale | 25,000 | $15.77 | $394.3K Sale | Form 4 ↗ |
| Sep 12, 2025 | Darrin Uecker Chief Technology Officer, Director | PLSE Pulse Biosciences, Inc | Sale | 25,000 | $14.32 | $358.0K Sale | Form 4 ↗ |
| Sep 11, 2025 | Darrin Uecker Chief Technology Officer, Director | PLSE Pulse Biosciences, Inc | Sale | 25,000 | $14.78 | $369.5K Sale | Form 4 ↗ |
| Sep 10, 2025 | Robert W. Duggan Director, 10% owner | PLSE Pulse Biosciences, Inc | Buy | 34,659 | $14.66 | $508.1K Buy | Form 4 ↗ |
| Jun 13, 2025 | Darrin Uecker Chief Technology Officer, Director | PLSE Pulse Biosciences, Inc | Sale | 15,000 | $15.98 | $239.7K Sale | Form 4 ↗ |
| Jun 12, 2025 | Darrin Uecker Chief Technology Officer, Director | PLSE Pulse Biosciences, Inc | Sale | 15,000 | $16.40 | $246.0K Sale | Form 4 ↗ |
| Dec 13, 2024 | Robert W. Duggan Director, 10% owner | PLSE Pulse Biosciences, Inc | Buy | 55,256 | $17.18 | $949.3K Buy | Form 4 ↗ |
| Dec 12, 2024 | Robert W. Duggan Director, 10% owner | PLES Pulse Biosciences, Inc | Buy | 45,404 | $17.13 | $777.8K Buy | Form 4 ↗ |
| Dec 11, 2024 | Burke Thomas Barrett | PLSE Pulse Biosciences, Inc | Sale | 50,000 | $17.42 | $871.0K Sale | Form 4 ↗ |
| Dec 11, 2024 | Robert W. Duggan Director, 10% owner | PLSE Pulse Biosciences, Inc | Buy | 50,000 | $17.42 | $871.0K Buy | Form 4 ↗ |
| Dec 11, 2024 | Robert W. Duggan Director, 10% owner | PLSE Pulse Biosciences, Inc | Buy | 6,054 | $16.74 | $101.3K Buy | Form 4 ↗ |
| Sep 12, 2024 | Robert W. Duggan Director, 10% owner | PLSE Pulse Biosciences, Inc | Buy | 145,140 | $14.41 | $2.1M Buy | Form 4 ↗ |
| Sep 11, 2024 | Robert W. Duggan Director, 10% owner | PLSE Pulse Biosciences, Inc | Buy | 12,800 | $14.77 | $189.1K Buy | Form 4 ↗ |
31 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:23 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances